

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Rexahn Pharmaceuticals Reports 2018 Financial Results

Mar 8 2019, 8:00 AM EST

Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients

Mar 4 2019, 8:00 AM EST

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

Mar 1 2019, 8:00 AM EST

Stock Overview

Symbol	RNN
Exchange	NYSE American
Market Cap	26.06m
Last Price	\$0.5398
52-Week	\$0.50 - \$2.38

03/25/2019 04:10 PM EDT

Investor Relations

ir@rexahn.com

Management Team

Douglas J. Swirsky

President and Chief Executive Officer

Ely Benaim, M.D.

Chief Medical Officer

Lisa Nolan, Ph.D.

Chief Business Officer

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.